Topic:

R&D

Latest Headlines

Latest Headlines

Boehringer takes a neuroscience approach to obesity with latest deal

Boehringer Ingelheim is pairing up with a small California biotech to explore the role circuits in the nervous system play in obesity, scouting for drug targets that could spur weight loss.

Pfizer, OrbiMed back $40M Rhythm round for rare genetic disease R&D

Boston-based Rhythm has gone back to the venture well to draw up a fresh $40 million in backing from some A-list investors to fuel a mid-stage program for rare genetic disorders linked with a lethal level of obesity.

Chorus grows for reform in vaccine development process

As the Ebola outbreak continues to wane in West Africa, vaccines experts are combing over what went wrong--and right--with the development of vaccine candidates against the virus.

UPDATED: Senseonics nabs $10M in venture funding for its implantable blood glucose monitor

Senseonics, the maker of an implantable continuous glucose monitor device, has picked up $20 million in venture funding, according to a regulatory filing.

Novavax reports positive top-line data from PhII trial of RSV vaccine

There is no vaccine for respiratory syncytial virus (RSV), which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65. But early data from Novavax's Phase II trial of its RSV candidate show its promise in protecting older adults.

AbbVie, Roche score a pivotal success with their 'breakthrough' cancer drug

A new oncology compound from AbbVie and Roche's Genentech division cleared its primary hurdle in a Phase II blood cancer trial, opening the door to an FDA filing by year's end.

Helius enters clinical trial of its PoNS brain stimulation device to treat traumatic brain injury

Helius Medical Technologies is set to begin a Phase III clinical trial with the U.S. Army Medical Research and Materiel Command for its Portable Neuromodulation Stimulator (PoNS), which is designed to treat balance disorder for patients with traumatic brain injury.

UPDATED: Nearing the brink, Eleven Bio bets on another PhIII eye study and shares soar

Less than three months after seeing its share price get crushed in the panic following a late-stage failure of its lead drug, Cambridge, MA-based Eleven Biotherapeutics is rolling the dice in a last-ditch effort to produce approval-worthy Phase III data.

Biocept partners with UC Irvine on liquid biopsy research

Liquid biopsy player Biocept is teaming up with the University of California, Irvine, to evaluate blood-based biomarkers (as opposed to tissue-based ones) in patients with metastatic cancers. The duo hopes to validate liquid biopsies as a treatment guide for precision medicines and develop a system for monitoring tumor mutations to identify signs of resistance to therapy.

What does Google's corporate shuffle mean for its biotech ambitions?

Google is divvying up its composite parts, becoming, depending on whom you ask, the new Berkshire Hathaway, the next General Electric or something heretofore never seen. But the move could have mixed implications for Google's nascent but growing life sciences empire.